Detalhe da pesquisa
1.
Transition from Paediatric to Adult Care in CAH: 20 Years of Experience at a Tertiary Referral Center.
Horm Metab Res
; 56(1): 45-50, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38171370
2.
Overnight 1 mg dexamethasone suppression test and 24 h urine free cortisol-accuracy and pitfalls when screening for Cushing's syndrome.
Pituitary
; 25(5): 693-697, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35821308
3.
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.
Pituitary
; 25(2): 296-307, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973139
4.
Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas.
Rev Endocr Metab Disord
; 21(2): 277-286, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415583
5.
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.
Rev Endocr Metab Disord
; 21(2): 243-251, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504268
6.
Multidisciplinary management of acromegaly: A consensus.
Rev Endocr Metab Disord
; 21(4): 667-678, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914330
7.
Biochemical diagnosis in prolactinomas: some caveats.
Pituitary
; 23(1): 9-15, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873848
8.
Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
Pituitary
; 23(2): 171-181, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31879842
9.
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Clin Endocrinol (Oxf)
; 91(6): 776-785, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31465533
10.
Management of Aggressive Pituitary Tumors - A 2019 Update.
Horm Metab Res
; 51(12): 755-764, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826270
11.
Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.
Pituitary
; 22(5): 476-487, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31338660
12.
Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.
Clin Endocrinol (Oxf)
; 86(4): 541-551, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27874199
13.
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
Pituitary
; 19(2): 149-57, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603536
14.
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.
Pituitary
; 19(1): 39-49, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377024
15.
A 12-month phase 3 study of pasireotide in Cushing's disease.
N Engl J Med
; 366(10): 914-24, 2012 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22397653
16.
Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.
Clin Endocrinol (Oxf)
; 82(1): 84-90, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143180
17.
Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Pituitary
; 18(2): 245-52, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25560275
18.
Diagnosis and management of prolactinomas: current challenges.
Pituitary
; 23(1): 1-2, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900881
19.
Pituitary-directed medical therapy in Cushing's disease.
Pituitary
; 18(2): 238-44, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25627118
20.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Clin Endocrinol (Oxf)
; 81(3): 408-17, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24533697